



Spring 2020  
**Publication List  
by Committee**



# Publication List by Committee

The publications listed below were received by the Group Chair's Office as published, accepted, and submitted or reflect change in status since the SWOG Fall 2019 SWOG Group Meeting. Conference abstracts are not included

## ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

### Published/Accepted Manuscripts

**MULTIPLE** Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. Roth ME, Unger JM, O'Mara AM, Lewis MA, Budd T, Johnson RH, Pollock BH, Blanke CD, Freyer DR. *Cancer Medicine* Feb 3. doi: 10.1002/cam4.2891. [Epub ahead of print], 2020.  
<https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2891>

### Submitted Manuscripts

(none this cycle)

## BARLOGIE-SALMON MYELOMA COMMITTEE

### Published/Accepted Manuscripts

**S0777/Other** Developments in Continuous Therapy and Maintenance Treatment Approaches for Patients With Newly Diagnosed Multiple Myeloma [review]. Dimopoulos DA, Jakubowiak AJ, McCarthy PL, Orłowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang J, Lu J, Sunami K, Lida S, Chng W-J, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC. *Blood Cancer Journal*, 10 (2), 17 2020 Feb 13.  
<https://www.nature.com/articles/s41408-020-0273-x>

**S1304** Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Ailawadhi S, Sexton R, Lentzsch S, Abidi M, Voorhees P, Cohen AD, Rohren E, Heitner S, Kelly KR, Mackler N, Baer DM, Hoering A, Durie BGM, Orłowski. *Clinical Cancer Research*, accepted 2020.

**CTN0102** Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. Giral S, Costa L, Maloney DG, Krishnan A, Fei M, Antin J, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash M, Sahebi F, Somlo G, Rowley S, Vogl D, Vesole D, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. *Biol Blood Marrow Transplant* Nov 9[Online ahead of print], 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31756536>

**E3A06** Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orłowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O'Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV. *Journal of Clinical Oncology* Oct 25 [Online ahead of print], 2019.  
[https://ascopubs.org/doi/full/10.1200/JCO.19.01740?url\\_ver=Z39.88-2003&rft\\_id=ori%3Arid%3Acrossref.org&rft\\_dat=crpub%3Dpubmed&](https://ascopubs.org/doi/full/10.1200/JCO.19.01740?url_ver=Z39.88-2003&rft_id=ori%3Arid%3Acrossref.org&rft_dat=crpub%3Dpubmed&)

**MULTIPLE\*** A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma among African Americans. Du Z, Weinhold N, Song C, Rand K, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Goodman P, Klein E, Zonder J, Orłowski R, Conti D, Haiman C, Cozen W. *Blood Advances* Jan 14;4(1):181-190, 2020. [\*S0000, S9217, Other Studies]  
<https://www.ncbi.nlm.nih.gov/pubmed/31935283>  
[see also Prevention & Epidemiology Cmte]

### Submitted Manuscripts

**S0120** Race-dependent differences in risk, genomics and Epstein-Barr virus exposure in monoclonal gammopathies (SWOG S0120). Dhodapkar M, Sexton R, Hoering A, van Rhee F, Barlogie B, Orłowski RZ. *JAMA Oncology*, submitted 2020.

**S077** Longer Term Follow-up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT). Durie BGM, Hoering A, Sexton R, Abidi M, Epstein J, Rajkumar V, Dispenzieri A, Thakuri M, Reu F, Reynolds CM, Orłowski RZ, Barlogie B. *Blood Cancer Journal*, submitted (provisionally accepted), 2020.

## BREAST COMMITTEE

### Published/Accepted Manuscripts

**S0221** Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Ambrosone C, Zirpoli G, Hutson A, McCann S, Barlow W, Kelly KM, Cannioto R, McCann W, Hershman D, Unger J, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M,

# Publication List by Committee

- Hortobagyi G, Gralow JR, Budd GT, Albain KS. *Journal of Clinical Oncology* Dec 19;JCO1901203. doi: 10.1200/JCO.19.01203. [Epub ahead of print], 2019. [see also Cancer Survivorship Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/31855498>
- S0307** Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/ Alliance/Canadian Cancer Trials Group (CCTG)/ ECOG-ACRIN/ NRG Oncology study S0307. Gralow JR, Barlow W, Paterson A, Miao J, Lew D, Stopeck A, Hayes D, Hershman D, Schubert M, Clemons M, Van Poznak C, Dees E, Ingle J, Falkson CI, Elias A, Messino M, Margolis J, Dakhil S, Chew H, Dammann K, Abrams J, Livingston R, Hortobagyi G. *Journal of the National Cancer Institute*, Oct 31. pii: djz215. doi: 10.1093/jnci/djz215. [Epub ahead of print], 2019. <https://www.ncbi.nlm.nih.gov/pubmed/?term=gralow+j+s0307>
- S0800** Analysis of pre- and post-treatment tissues from the SWOG S0800 trial reveals an effect of neoadjuvant chemotherapy on the breast cancer genome. Powles R, Wali V, Li X, Barlow W, Nahleh Z, Thompson A, Godwin A, Hatzis C, Pusztai L. *Clinical Cancer Research*, published online January 9, 2020; doi: 10.1158/1078-0432.CCR-19-2405. <https://clincancerres.aacrjournals.org/content/early/2020/02/28/1078-0432.CCR-19-2405>
- S1501** The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment- Related Cardiovascular Toxicity. Minasian L, Dimond E, Davis M, Adhikari B, Fagerstrom R, Fabian C, Floyd J, Unger J, Douglas P, Mustian K, Chow EJ, Lipshultz S, Hundley G, Armenian S, Ky B. *JACC: Cardiooncology* Sept 1(1):105-113, 2019. <https://cardiooncology.onlinejacc.org/content/1/1/105> (see also Cancer Survivorship Cmte)
- S8814** The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814. Woodward WA, Barlow WE, Jaggi R, Buchholz TA, Shak S, Baehner F, Yoshizawa CN, Whelan TJ, Davidson NE, Ingle JN, King TN, Ravdin PM, K. Osborne CK, Tripathy D, Livingston RB, Gralow JR, Hortobagyi GN, Hayes DF, Albain KS. *JAMA Oncology*, Jan 9. [Epub ahead of print], 2020. <https://www.ncbi.nlm.nih.gov/pubmed/?term=woodward+w+s8814>
- S9313** Validation of the DNA Damage Immune Response (DDIR) Signature in Triple-Negative Breast Cancer (TNBC) Patients from the SWOG 9313c Trial. Sharma P, Barlow W, Godwin A, Parkes E, Knight L, Walker SM, Kennedy RD, Harkin D, Logan G, Steele CJ, Lambe S, Badve S, Gokmen-Polar Y, Pathak H, Isakova K, Linden HM, Porter P, Pusztai L, Thompson AM, Tripathy D, Hortobagyi G, Hayes D. *Journal of Clinical Oncology*, Dec 20;37(36):3484-3492, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/?term=sharma+p+9313c>
- B47** NSABP B-47 / NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy with or without Trastuzumab in High-risk Invasive Breast Cancer Negative for HER2 by ISH and with IHC 1+ or 2+ (HER2-low). Fehrenbacher L, Cecchini R, Geyer CE, Rastogi P, Costantino J, Atkins JN, Crown JP, Polikoff J, Boileau J-F, Provencher L, Stokoe C, Moore TD, Robidoux A, Flynn PJ, Borges VF, Albain KS, Swain SM, Paik S, Mamounas EP, Wolmark N. *Journal of Clinical Oncology*, Feb 10; 38 (5), 444-453, 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31821109>
- C49907** Adjuvant Chemotherapy with Standard Regimens versus Capecitabine in Older Women with Early Stage Breast Cancer: 10-year update of Alliance/CALGB trial 49907. Muss H, Polley M, Berry DA, Liu H, Cirincione C, Theodoulou M, Mauer A, Kornblith A, Partridge A, Dressler LG, Cohen HJ, Becker H, Kartcheske P, Wheeler J, Perez EA, Wolff A, Gralow J, Burstein H, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria Arti, Norton L, Hudis C, Winer E, Carey L. *Journal of Clinical Oncology* Sep 10;37(26):2338-2348, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31339827>
- PACCT-1** Clinical Outcomes in Women with Early Breast Cancer and a High 21-Gene Recurrence Score of 26-100 Assigned to Receive Adjuvant Chemotherapy plus Endocrine Therapy: A Secondary Analysis of a Prospective Clinical Trial. *JAMA Oncology* Sep 30[Online ahead of print], 2019. Sparano JA, Gray RJ, Makower D, Pritchard K, Albain KS, Hayes DF, Geyer CE, Dees E, Goetz M, Olson JA, Lively T, Badve S, Saphner TJ, Wagner LI, Whelan T, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins T, Mayer I, Brufsky A, Toppmeyer D, Kaklamani V, Berenberg J, Sledge G. [https://pubmed.ncbi.nlm.nih.gov/31566680-clinical-outcomes-in-early-breast-cancer-with-a-high-21-gene-recurrence-score-of-26-to-100-assigned-to-adjuvant-chemotherapy-plus-endocrine-therapy-a-secondary-analysis-of-the-tailorx-randomized-clinical-trial/?from\\_term=sparano+j+2019](https://pubmed.ncbi.nlm.nih.gov/31566680-clinical-outcomes-in-early-breast-cancer-with-a-high-21-gene-recurrence-score-of-26-to-100-assigned-to-adjuvant-chemotherapy-plus-endocrine-therapy-a-secondary-analysis-of-the-tailorx-randomized-clinical-trial/?from_term=sparano+j+2019)

## Submitted Manuscripts

- S0221** Exercise before, during and after chemotherapy for high-risk breast cancer in a therapeutic trial (S0221); relationships with recurrence and survival. Cannioto RA, Hutson A, Dighe S, McCann W, McCann S, Zirpoli G, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow J, Albain K, Budd GT, Ambrosone C. *JNCI*, under revision for resubmission, 2020. [see also Cancer Survivorship Cmte]

# Publication List by Committee

## CANCER CONTROL AND PREVENTION

### Cancer Care Delivery Committee

#### Published/Accepted Manuscripts

**S1105** Randomized Trial of Text-Messaging to Reduce Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women with Early Stage Breast Cancer: SWOG S1105. Hershman DL, Unger JM, Clarke Hillyer G, Moseley A, Arnold K, Dakhil S, Esparaz B, Kuan M, Graham ML, Lackowski D, Edenfield W, Dayao Z, Henry NL, Gralow J, Ramsey S, Neugut A. *Journal of Clinical Oncology*, accepted 2020.

**S9916** A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events. Lee SM, Miao J, Unger JM, Cheung K, Hershman DL. *Health and Quality of Life Outcomes* Aug 22;17(1):146, 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31438967>

**MULTIPLE\*** Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-world Experiment. Kim DD, Guzauskas G, Bennette C, Basu A, Veenstra D, Ramsey S, Carlson J. *PharmacoEconomics*, Feb;38(2):171-179, 2020. [\*S1418, S1513].

<https://www.ncbi.nlm.nih.gov/pubmed/31631254>

**MULTIPLE\*** Association of Patient Demographics and Insurance Status with Survival in Cancer Clinical Trials with Positive Findings. Unger JM, Blanke CD, LeBlanc M, Barlow W, Vaidya R, Fleury M, Ramsey SD, Hershman DL. *JAMA Network Open*, accepted 2020.

[\*S0200, S0777, S8494, S8501, S8591, S8624, S8710, S8736, S8797, S8814, S8892, S8897, S8949, S9008, S9126, S9210, S9226, S9308, S9916, MULTIPLE]

**MULTIPLE\*** The Association of NCI-Sponsored Network Group Clinical Trials and Guideline Care and New Drug Indications. Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD. [\*multiple SWOG and other NCTN-led trials]. *JAMA Open Network*, Sep 4;2(9):e1910593. doi: 10.1001/jamanetworkopen.2019.10593, 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31483471>

**N/A** Reproducible Findings in Systematic Reviews and Meta-analyses in Oncology: Verify, Then Trust [editorial/opinion]. Unger JM. *JAMA Oncol* 2019 Sep 5 [Online ahead of print].

<https://jamanetwork.com/journals/jamaoncology/article-abstract/2749252>

#### Submitted Manuscripts

**S1417CD** Design, Data Linkage, and Implementation Considerations in

the First Cooperative Group Led Study Assessing Financial Outcomes in Cancer Patients and their Informal Caregivers (SWOG S1417CD). Shankaran V, Unger J, Darke A, Hershman DL, Ramsey SD. *Clinical Trials*, submitted 2020.

**MULTIPLE** Racial Representativeness of Cancer Clinical Trials Sponsored by the National Cancer Institute Compared to Pharmaceutical Companies. Unger J, Hershman D, Osarogiagbon R, Gothwal A, Anand S, Dasari NA, Overman M, Loree J, Raghav K. *JNCI Cancer Spectrum*, submitted 2020.

**MULTIPLE\*** Economic evaluations in NCI-sponsored network cancer clinical trials. Nghiem VT, Vaidya R, Lyman GH, Hershman DL, Ramsey SD, Unger JM. *Value in Health*, submitted 2020. [\*E2100, E4494, IBCSG25, JMA17, N9741, N9831, S8494, S8710, S8794, S8797, S9031, S9412, S9509]

## Cancer Survivorship Committee

#### Published/Accepted Manuscripts

**S0221** Vitamin supplement use during chemotherapy and survival outcomes of breast cancer patients enrolled in a cooperative group clinical trial (SWOG S0221). Ambrosone C, Zirpoli G, Hutson A, McCann S, Barlow W, Kelly KM, Cannioto R, McCann W, Hershman D, Unger J, Moore HCF, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi G, Gralow JR, Budd GT, Albain KS. *Journal of Clinical Oncology* Dec 19;JCO1901203. doi: 10.1200/JCO.19.01203. [Epub ahead of print], 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31855498>

[see also Breast Cmte]

**S1501** The Evolving Design of NIH-Funded Cardio-Oncology Studies to Address Cancer Treatment-Related Cardiovascular Toxicity. Minasian L, Dimond E, Davis M, Adhikari B, Fagerstrom R, Fabian C, Floyd J, Unger J, Douglas P, Mustian K, Chow EJ, Lipshultz S, Hundley G, Armenian S, Ky B. *JACC: Cardiooncology* Sept 1(1):105-113, 2019.

<https://cardiooncology.onlinejacc.org/content/1/1/105>

[see also Breast Cmte]

#### Submitted Manuscripts

**S0221** Exercise before, during and after chemotherapy for high-risk breast cancer in a therapeutic trial (S0221); relationships with recurrence and survival. Cannioto RA, Hutson A, Dighe S, McCann W, McCann S, Zirpoli G, Barlow W, Kelly KM, DeNysschen CA, Hershman DL, Unger JM, Moore HCF, Stewart JA, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralow J, Albain K, Budd GT, Ambrosone C. *JNCI*, under revision for resubmission, 2020. [see also Breast Cmte]

# Publication List by Committee

## Palliative and End of Life Care Committee

### Published/Accepted Manuscripts

**S1316** Intellectual Equipoise and Challenges: Accruing Patients with Advanced Cancer to a Trial Randomizing to Surgical or Non-Surgical Management (SWOG S1316). Deutsch G, Deneve J, Al-Kasspooles M, Nfonsam V, Gunderson C, Alvarez Secord A, Rodgers P, Hendren S, Silberfein E, Grant ML, Sloan J, Sun V, Arnold K, Anderson G, Krouse R. *American Journal of Hospice & Palliative Medicine* Jan 37 (1):2-18, 2020. <https://journals.sagepub.com/doi/abs/10.1177/1049909119851471>

**N/A** The Gift of Dying with Control. Blanke CD. *Practical Radiation Oncology* Nov;9(6):387-388, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31525423>

**N/A** Physician-Assisted Suicide (PAS)/Physician Aid in Dying (PAD) at the End of the Day. O'Rourke MA. *Practical Radiation Oncology* Nov; 9(6):384-386,2019. [https://www.practicalradonc.org/article/S1879-8500\(19\)30266-8/fulltext](https://www.practicalradonc.org/article/S1879-8500(19)30266-8/fulltext)

**N/A** In reply to Daniel Sulmasy's invited commentary, "Physician-assisted suicide and the perils of empirical ethical research". *JAMA Network Open* 2019 Aug 2 [Sept16];2(8):e198628. doi: 10.1001/jamanetworkopen. Blanke CD. 2019. PMID31397854. <https://www.ncbi.nlm.nih.gov/pubmed/31397854>

**N/A** Trends in Medical Aid in Dying in Oregon and Washington. Al Rabadi L, LeBlanc M, Bucy T, Ellis LM, Hershman DL, Meyskens FL, Jr, Taylor L, Blanke CD. *JAMA Network Open*, Aug 2;2(8):e198648, 2019 <https://www.ncbi.nlm.nih.gov/pubmed/31397857>

**PILOT** Clinical Work Intensity Among Medical Oncologists Practicing in National Community Oncology Research Program Community Sites. Hudson MF; O'Rourke MA, Blackhurst DW, Caldwell J, Horner RD. *Journal of Oncology Practice* Oct; 5(10):e870-e877, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31335248>

### Submitted Manuscripts

**PILOT (S1820)** Altering Intake and Managing Symptoms in Rectal Cancer (AIMS-RC): Feasibility of a Diet Modification Intervention for Post-Treatment Bowel Dysfunction [pilot for S1820]. Sun V, Crane T, Wright S, Chanson D, Slack S, Yung A, Sentovich S, Melstrom K, Fakih M, Krouse R, Thomson CA. *Nutrition and Cancer*, submitted 2020.

## Prevention and Epidemiology Committee

### Published/Accepted Manuscripts

**S9217** Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Hurwitz L, Kulac I, Gumuskaya B, Baena-Del Valle J, Benedetti I, Pan F, Liu JO, Marrone M, Arnold K, Goodman P, Tangen C, Lucia MS, Thompson IM, Drake CG, Isaacs W, Nelson W, De Marzo A, Platz EA. *Cancer Epidemiology, Biomarkers & Prevention* Mar;28(3):563-569, 2019. PMID30487131; PMC6401240. <https://www.ncbi.nlm.nih.gov/pubmed/30487131>

**S9217** 5a-Reductase Inhibitor Use in Patients With Prostate Cancer [Letter to the Editor/Comment & Response] re: Sarkar RR, Parsons JK, Bryant AK, et al.]. Thompson IM, Tangen CM, Kramer B. *JAMA Internal Medicine* Oct 1;179(10):1440, 2019. PMID31589258. <https://www.ncbi.nlm.nih.gov/pubmed/31589258>

**S9217** Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial. Torkko KC, Till C, Tangen CM, Goodman P, Schenk Kisser JM, Song X, Lucia MS, van Bokhoven A, Peters U, Thompson IM, Neuhaus ML. *Cancer Prevention Research*, accepted 2020. <https://cancerpreventionresearch.aacrjournals.org/content/early/2020/02/26/1940-6207.CAPR-19-0413>

**S9217** Association of treatment with 5a-reductase inhibitors with time to diagnosis and mortality in prostate cancer. Thompson IM, Tangen CM, Kramer B. Letter to the Editor re: Sarkar RR, Parsons JK, Bryant AK, et al. *JAMA Internal Medicine*, accepted 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31058923>

**S0000** Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI. Tangen C, Schenk J, Till C, Goodman P, Barrington W, Lucia M, Thompson I. *Cancer Epidemiology* Dec 63:101619, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31639607>

**S0000/S9217** Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate. Ahmed M, Goh C, Saunders E, Cieza-Borella C, Consortium PRACTICAL, Kote-Jarai Z, Schumacher F, Eeles R. *Cancer and Prostatic Diseases* Nov 27 [Epub ahead of print], 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31776447>



# Publication List by Committee

**S0000/Other** A Transcriptome-Wide Association Study (TWAS) Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Zhong J, Jermusyk A, Wu L, Hoskins JW, Collins I, Mocci E, Albanes D, Fuchs C, Goodman GE, Goodman PJ, Klein EA, Petersen GM, Zheng W, Amundadottir LT [see article for complete author list]. *Journal of the National Cancer Institute* 2020 Jan 9 [Online ahead of print]. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz246/5698709>

**C70807** Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Parsons JK, Zariwala D, Mohler J, Paskett E, Hansel D, Kibel A, Liu H, Seisler D, Natarajan L, Hahn O, Taylor J, Small E, Van Veldhuizen P, Morris MJ, Bertagnolli M, Stroup S, Pierce JP, Marshall J. *JAMA* Jan 14;323(2):140-148, 2020 <https://jamanetwork.com/journals/jama/article-abstract/2758598> [see also GU Cmte]

**MULTIPLE\*** Measures of Body Fatness and Height Across the Adult Lifecourse and Risk of Prostate Cancer Incidence and Mortality in the Pooling Project of Prospective Studies of Diet and Cancer. Genkinger JM, Wu K, Wang M, Albanes D, Black A, van den Brandt P, Cook MB, Gapstur SM, Giles GG, Giovannucci E, Goodman G, Goodman P, Hakansson N, Key T, Mannisto S, Le Marchand L, Liao L, MacInnis R, Neuhauser M, Platz E, Sawada N, Schenk Kisser J, Stevens VL, Travis RC, Tsugane S, Viswanathan K, Wilkens RL, Wolk A, Smith-Warner SA. *Annals of Oncology*, Jan;31(1):103-114, 2020. [\*S9217, other studies] <https://www.ncbi.nlm.nih.gov/pubmed/31912782>

**MULTIPLE\*** Cumulative Burden of Colorectal Cancer-Associated Genetic Variants is More Strongly Associated With Early-onset vs Late-onset Cancer. Archambault A, Su Y-R, Jeon J, Minta T, Lin Y, Conti D, Albanes D, Goodman P, Platz E, Tangen C, Lenz H-J, Corley D, Hsu L, Peters U, Hayes R. *Gastroenterology* Dec 19 [Epub ahead of print], 2019. [\*S0000, other studies] <https://www.ncbi.nlm.nih.gov/pubmed/31866242>

**MULTIPLE\*** A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma among African Americans. Du Z, Weinhold N, Song C, Rand K, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Goodman P, Klein E, Zonder J, Orlowski R, Conti D, Haiman C, Cozen W. *Blood Advances*, Jan 14;4(1):181-190, 2020 accepted 2019. [\*S0000, S9217, other studies] <https://www.ncbi.nlm.nih.gov/pubmed/31935283> [see also Myeloma Cmte]

## Submitted Manuscripts

**S0000** Selection and verification propensity matching in external validation studies. Chen Y, Pfeiffer R, Shepherd B, Ankerst D. *Epidemiology*, submitted 2020.

**S0000/S9217** Prostate Cancer Prevention: A Perspective. Thompson IM, Tangen C. *Science*, under revision for resubmission, 2020.

**S0000B** Age-related Macular Degeneration in a Randomized Trial of Selenium and Vitamin E in Men: The SELECT Eye Endpoints (SEE) Study (SWOG S0000B). Christen W, Darke A, Gaziano JM, Glynn RJ, Goodman P, Crowley J, Lippman SM, Lad TE, Bearden JD, Goodman GE, Minasian LM, Thompson IM, Blanke CD, Klein EA. *Ophthalmic Epidemiology*, under review 2020.

**S0820/other** Effect of Increasing Trust in Medical Researchers on Minority Recruitment: The RECRUIT Randomized Clinical Trial. Tilley BC, Mainous AG, Amorrortu RP, McKee MD, Smith DW, Li R, DeSantis SM, Vernon SW, Alvidrez J and additional RECRUIT Trial Center and Parent Trials' investigators [including Zell J, Yee M and Unger J]. *American Journal of Public Health*, under revision for resubmission 2020.

**MULTIPLE\*** Dysregulated super-enhancers in colorectal cancer are beacons for discovering genetic risk loci. Bien S, Harrison T, Huyghe J, Lu Y, Wang H, Shcherbina A, Albanes D, Goodman P, Platz E, Tangen C, Le Marchand L, Zheng W, Gruber S, Hsu L, Schacherer P, Peters U. *Nature Communications*, under revision for resubmission, 2020. [\*S0000, other studies]

**MULTIPLE\*** A functional variation in PSA that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer. Srinivasan S, Kryza T, Bock N, Stephens C, Dong Y, Panchadsaram J, Moya L, Rohl J, Perry-Keene J, Buzacott K, Gago M, Schleutker J, Maier C, Muir K, Tangen C, Gronberg H, Pashayan N, Albanes D, Wolk A, Eeles R, Clements J, Batra J. *Nature Genetics*, under review 2020. [\*S0000, S9217, other studies]

## Symptom Control and Quality of Life Committee

### Published/Accepted Manuscripts

(none this cycle)

### Submitted Manuscripts

**S1013** A Prospective Study to Validate the FACT-EGFRI 18 Questionnaire for Epidermal Growth Factor Receptor Inhibitor (EGFRI)-Induced Dermatologic Toxicities: SWOG S1013. Wong S-F, Unger JM, Wade JL, Wagner L, Lacouture M, Humphries K, Moseley A, Arnold K, Velasco M,

# Publication List by Committee

Floyd J, Esparaz B, Barzi A, Lenz H-J, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. Journal of Patient Reported Outcomes, under review 2020.

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Journal of Patient Reported Outcomes, under review 2020. [see also GI Committee]

## DIGITAL ENGAGEMENT COMMITTEE

### Published/Accepted Manuscripts

**N/A** Clinical Trials in the Era of Digital Engagement: A SWOG Call to Action. Gunturu K, Dizon D, Johnson J, Mercurio AM, Mason G, Sparks D, Lawton W, Klemp J. JCO Clinical Cancer Informatics, accepted 2020.

### Submitted Manuscripts

(none this cycle)

## EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

### Published/Accepted Manuscripts

**S1609** A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Neuroendocrine Cohort. Patel S, Othus M, Chae Y, Giles F, Hansel D, Singh P, Fontaine A, Shah M, Kasi A, Al Baghdadi T, Vasireddy S, Mayerson E, Ryan CW, Plets Melissa, Blanke CD, Kurzrock R. Clinical Cancer Research, Jan 22. pii: clincanres.3356.2019. doi: 10.1158/1078-0432.CCR-19-3356. [Epub ahead of print] 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31969335>

### Submitted Manuscripts

**S1609** Dual Checkpoint Blockade in a Neuroendocrine Carcinoma with Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden [case report]. Gong J, Adashek D, Frishberg D, Guan M, Placencio-Hickock V, Gangi A, Gresham G, Tuli R, Othus M, Chae YK, Kurzrock R, Hendifar A. JCO Precision Oncology, submitted 2020.

## GASTROINTESTINAL COMMITTEE

### Published/Accepted Manuscripts

**S1201** A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients with Advanced/Metastatic Esophageal, Gastric

or Gastroesophageal Junction Cancer Based on Gene Expression of ERCC1: SWOG S1201. Iqbal S, McDonough S, Lenz H-J, Ilson D, Burtness B, Nangia C, Barzi A, Schneider CJ, Liu J, Dotan E, Guthrie K, Hochster H. Journal of Clinical Oncology, Feb 10;38(5):472-479, 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31815582>

**S1310** Randomized Phase II Trial (SWOG S1310) of Single Agent MEK Inhibitor Trametinib vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer. Kim R, McDonough S, El-Khoueiry A, Bekaii-Saab T, Stein S, Sahai V, Keogh G, Kim E, Baron A, Siegel A, Barzi A, Guthrie K, Javle M, Hochster H. European Journal of Cancer, accepted 2020.

**C/S8040** Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Yuan C, Sato K, Hollis B, Zhang S, Niedzwiecki D, Ou F-S, Chang I-W, O'Neil BH, Innocenti F, Lenz H-J, Blanke C, Venook A, Mayer R, Fuchs C, Meyerhardt J, Ng K. Clinical Cancer Research, 25 (24), 7497-7505, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31548349>

**C/S80405** Associations of Physical Activity with Survival and Progression in Metastatic Colorectal Cancer: Results from CALGB(Alliance)/SWOG 80405. Guercio B, Zhang S, Ou F-S, Venook A, Niedzwiecki D, Lenz H-J, Innocenti F, O'Neil B, Shaw JE, Polite B, Hochster H, Atkins J, Goldberg R, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly E, Fuchs C, Meyerhardt J. Journal of Clinical Oncology Aug 6 [Epub ahead of print] Oct 10;37(29):2620-2631, 2019. PMID31408415. <https://www.ncbi.nlm.nih.gov/pubmed/31408415>

**C/S80405** Diabetes and Clinical Outcome in Patients with Metastatic Colorectal Cancer: CALGB 80405 (Alliance). Brown JC, Zhang S, Ou F-S, Venook A, Niedzwiecki D, Lenz H-J, Innocenti F, O'Neil BH, Shaw JE, Polite B, Hochster H, Atkins JN, Goldberg RM, Ng K, Meyer RJ, Blanke CD, O'Reilly E, Fuchs CS, Meyerhardt JA. JNCI Cancer Spectrum Volume 4, Issue 1, February 2020. <https://academic.oup.com/jncics/article/4/1/pkz078/5588850>

**C80802** A phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma CALGB 80802 (Alliance). Abou-Alfa G, Shi Q, Knox J, Kaubisch A, Niedzwiecki D, Posey J, Tan B, Kavan P, Goel R, Lammers P, Bekaii-Saab T, Tam VC, Rajdev L, Kelley R, El-Khoueiry A, El Dika I, Zemla T, Potaracke R, Balletti J, Schwartz L, Goldberg RM, Bertagnolli M, Meyerhardt J, O'Reilly E, Venook A. JAMA Oncology 5 (11), 1582-1588, 2019. [https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4\\_suppl.192](https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.192)

# Publication List by Committee

**R0848** Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial. Abrams RA, Winter KA, Safran H, Goodman Karyn A, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S MD, Willett, CG, Crane CH. *American Journal of Clinical Oncology*, Mar; 43 (3);173-179, 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31985516>

## Submitted Manuscripts

**S1406** Randomized trial of irinotecan an cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). Kopetz S, Guthrie K, Morris V, Lenz H-J, Magliocco A, Maru D, Airhart S, Yan Y, Lanman R, Manyam G, Hong D, Sorokin A, Atreya C, Allegra C, Raghav K, Wang S, Lieu C, McDonough S, Philip P, Hochster H. *Cancer Discovery*, submitted 2020.

**S1505** Defining Resectability: Initial Lessons from SWOG S1505 (NCT #02562716): A Randomized Phase II Trial for Resectable Pancreatic Adenocarcinoma [Brief Communication]. Sohal D, Duong M, Ahmad S, Gandhi N, Beg MS, Wang-Gillam A, Wade J, Chiorean E, Guthrie K, Lowy A, Philip P, Hochster H. *Journal of the National Cancer Institute*, submitted 2020.

**N0147** Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. *Journal of Patient Reported Outcomes*, under review 2020. [see also SCQOL Cmte]

## GENITOURINARY COMMITTEE

*Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees*

## Published/Accepted Manuscripts

**S0925** Survival Outcomes and Risk Group Validation from SWOG S0925, A Randomized Phase II Study of Cixutumumab in New Metastatic Hormone-Sensitive Prostate Cancer. Wong R, Duong M, Tangen C, Agarwal N, Cheng H, Vogelzang N, Hussain M, Thompson I, Quinn D, Yu E. *Prostate Cancer and Prostatic Disease*, Feb 13 [Epub ahead of print] 2020. <https://www.ncbi.nlm.nih.gov/pubmed/32055002>

**S0931** Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis

for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Synold T, Plets M, Tangen C, Heath E, Palapattu G, Mack P, Stein M, Meng M, Lara P, Vogelzang N, Thompson IM, Ryan CR. *Kidney Cancer*, Aug 7;3(2):111-118, 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31763512>

**S1314** Review of SWOG S1314: Lessons from a randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer [Review]. Boxley P, Plets M, Flaig. *Bladder Cancer*, accepted 2020.

**C70807** Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. Parsons JK, Zariw D, Mohler J, Paskett E, Hansel D, Kibel A, Liu H, Seisler D, Natarajan L, Hahn O, Taylor J, Small E, Van Veldhuizen P, Morris MJ, Bertagnolli M, Stroup S, Pierce JP, Marshall J. *JAMA* Jan 14;323(2):140-148, 2020. <https://www.ncbi.nlm.nih.gov/pubmed/31935026> [see also Prevention & Epidemiology Cmte]

**E3805** HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Hearn J, Sweeney CJ, Almassi N, Reichard C, Reddy CA, Li H, Hobbs B, Jarrard D, Chen Y-H, Dreicer R, Garcia J, Carducci M, DiPaola R, Sharifi N. *JAMA Oncology*, accepted 2020.

**EA8141** Results of a Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. Margulis V, Puliigandla M, Trabulsi E, Plimack E, Kessler E, Matin S, Godoy G, Alva A, Hahn N, Carducci M, Hoffman-Censits J. *Journal of Urology* Nov 8;101097JU0000000000000644.[Epub ahead of print], 2019. <https://www.ncbi.nlm.nih.gov/pubmed/31702432>

## Submitted Manuscripts

**S1314** A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowler J, Gustafson D, Plets M, Thompson IM. *Journal of Clinical Oncology*, submitted 2020.

## LEUKEMIA COMMITTEE

## Published/Accepted Manuscripts

**S1203** Rapid Donor Identification Improves Survival in High Risk First Remission AML Patients. Pagel J, Othus M, Garcia-Manero G, Fang M, Radich J, Rizzieri D, Marcucci G, Strickland S, Litzow M, Savoie ML,



# Publication List by Committee

Spellman S, Confer D, Chell J, Brown M, Medeiros B, Lin T, Uy G, Powell B, Bayer R, Larson RA, Stone RM, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Erba H, Appelbaum F. *Journal of Oncology Practice* Jan 27 [Epub ahead of print].

<https://www.ncbi.nlm.nih.gov/pubmed/32048933>

**E1912** Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. Shanafelt TD, Wang XV, Hanson C, O'Brien S, Barrietos J, Barrietos J, Jelinek DF, Braggio D, Leis J, Zhang CC, Coutre SE, Barr P, Cashen A, Mato A, Singh A, Mullane MP, Little RF, Erba HP, Stone RM, Litzow M, Tallman MS. *New England Journal of Medicine* Aug 1;381(5):432-443, 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31365801>

**MULTIPLE\*** Allogeneic Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation in older Acute Myeloid Leukemia (AML) Patients 60-75 Years in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study. Ustun C, Le-Rademacher J, Wang H-L, Othus M, Sun Z, Major B, Zhang M-J, Storricks E, Lafky J, Chow S, Mrozek K, Attar E, Bloomfield C, Cripe L, Tallman M, Appelbaum F, Nand S, Larson R, Marcucci G, Roboz G, Uy GL, Stone RM, Jatoi A, Shea T, di Lima M, Foran J, Sandmaier B, Litzow M, Erba H, Hurria A, Weisdorf D, Artz A. *Leukemia* Nov;33(11):2599-2609, 2019. [\*A151509,S0432,S0703,MULTIPLE]

<https://www.ncbi.nlm.nih.gov/pubmed/31073153>

**MULTIPLE\*** Bias in mean survival from fitting cure models with limited follow-up. Othus M, Bansal A, Erba H, Ramsey S. *Value in Health*, accepted 2020. [\*S0106,S0325,S0703,S0805,S1117,S1203]

## Submitted Manuscripts

**S053** A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia (SWOG S0535). Lancet JE, Moseley AB, Komrokj RS, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, Litzow MR, Erba HP, Appelbaum FR. *Blood Advances*, under revision for resubmission 2020.

**S1203** Standard versus high-dose cytarabine with or without vorinostat for AML. Garcia-Manero G, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland SA, Litzow MR, Savoie M, Medeiros B, Sekeres M, Lin TL, Uy G, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba HP. *Leukemia*, under review 2020.

**MULTIPLE** Association of immunophenotype with expression of topoisomerase II  $\alpha$  and  $\beta$  in adult acute myeloid leukemia. Michelson A, McDonough S, Willman C, Koegle E, Godwin J, Petersdorf S, List A, Othus

M, Appelbaum F, Radich J, Ganapathi R, Advani A, Ganapathi R. *Scientific Reports*, accepted 2020. [\*S9031, S9126, S9333 and S9500].

**MULTIPLE\*** AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors:A SWOG Report. Era L, Pogossova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen I-M L, Erba HP, Godwin JE, Jenkins IC, Fang M, Huyhn M, Kopecky KJ, List AF, Naru J, Pogossova GL, Radich JP, Stevens E, Willborg B, Willman CL, Wood BL, Zhang Q, Meshinchi S, Stirewalt DL. *British Journal of Haematology*, submitted 2020. [\*S0106, S0112, S9031, S9333]

**MULTIPLE\*** Associations Between Complete Remission and 2-3 Year Survival Following 7+3 Induction for Acute Myeloid Leukemia. Othus M, Garcia-Manero G, Godwin J, Weick J, Stirewalt D, Appelbaum F, Erba H, Estey E. *Leukemia*, under review 2020. [\*S0106,S1203,S8600,S9031,S9333]

## LUNG COMMITTEE

### Published/Accepted Manuscripts

**N0923** A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study. Schenk E, Mandrekar S, Dy G, Aubry M, Tan AD, Dakhil S, Wadsworth TW, Sachs B, Nieva J, Rudin C, Poitier J, Molina JR. *Journal of Thoracic Oncology* Oct 9 [Epub ahead of print], 2019.

<https://www.ncbi.nlm.nih.gov/pubmed/31605793>

**MULTIPLE\*** The accuracy of clinical staging of stage I-III non-small cell lung cancer: An analysis based on individual participant data. Navani N, Fisher D, Tierney J, Burdett S; NSCLC Meta-analysis Collaborative Group; SWOG Collaborators: Bunn PA, Vallieres E. *Chest* Mar;155(3):502-509, 2019. [\*S9900,MULTIPLE]

<https://www.ncbi.nlm.nih.gov/pubmed/30391190>

**MULTIPLE\*** EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis [Review]. Agustoni F, Suda K, Yu H, Ren S, Rivard CJ, Ellison K, Caldwell C, Roseboom L, Brovsky KA, Hirsch F. *Cancer Treatment Reviews* Jan;72:15-27, 2019. [\*S0342,S0536,S0819, other]

<https://www.ncbi.nlm.nih.gov/pubmed/30445271>

### Submitted Manuscripts

(none this cycle)

# Publication List by Committee

## LYMPHOMA COMMITTEE

### Published/Accepted Manuscripts

**S1106** Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc M, Fenske TS, Shea TC, Barr P, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. *Blood Advances*, 3(20):3132-3135, 2019..

<https://www.ncbi.nlm.nih.gov/pubmed/31648328>

### Submitted Manuscripts

**S0816** Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Analysis of SWOG S0816. Ha CS, Leblanc M, Schoder H, Pinnix C, Brem E, Bartlett N, Evens AM, Hsi ED, Rimsza L, Leonard JP, Kahl BS, Li H, Smith SM, Constine LS, Friedberg JW. *Leukemia & Lymphoma*, submitted 2020.

**S1001** PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup NCTN Study S1001. Persky D, Li H, Stephens D, Park S, Bartlett N, Swinnen L, Barr P, Winegarden J, Constine L, Fitzgerald T, Leonard J, Kahl B, LeBlanc M, Song J, Fisher R, Rimsza L, Smith S, Miller T, Friedberg JW. *New England Journal of Medicine*, submitted 2020.

**CTSU/9177** Risk-Adapted DA-EPOCH-Rituximab Therapy in Adults with Untreated Burkitt Lymphoma. Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link B, Patel P, Bierman PJ, Jagadeesh D, Parekh S, Nagpal S, O'Brien TE, Mitsuyasu R, Peace D, Watson PR, Battini R, Hanna W, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little R, Bartlett NL, Finale M, Noy A, Wilson WH. *Journal of Clinical Oncology*, submitted (provisionally accepted) 2020.

## MELANOMA COMMITTEE

### Published/Accepted Manuscripts

**E1609** Phase III Study of Adjuvant Ipilimumab (3 or 10 Mg/Kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. Tarhini AA, Lee SJ, Hodi FS, Rao U, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. *Journal of Clinical Oncology*, Feb 20; 38(6):567-575, 2020.

<https://www.ncbi.nlm.nih.gov/pubmed/31880964>

### Submitted Manuscripts

**S0826** SWOG S0826: A phase II trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma. Lao CD, Moon J, Fruehauf JP, Flaherty LE, Bury MJ, Ribas A, Sondak VK. *Cancer*, under review 2020 .

**S1320** Continuous compared to intermittent therapy for BRAF mutated melanoma. Algazi A, Othus M, Othus M, Daud A, Lo R, Mehnert J, Truong T-G, Conry R, Kendra K, Doolittle G, Clark J, Messino M, Moore D, Lao C, Faller B, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann K, Ribas A. *New England Journal of Medicine*, 2020.

## PHARMACEUTICAL SCIENCES COMMITTEE

### Published/Accepted Manuscripts

**MULTIPLE** Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy. Marcath LA, Finley C, Wong S-F, Hertz DL. *BMC Cancer*, accepted 2020.

### Submitted Manuscripts

**MULTIPLE** Development of a tool for detecting drug-drug interactions during oncology clinical trial enrollment eligibility screening. Marcath LA, Coe T, Shakeel F, Reynolds E, Bayuk M, Haas S, Redman BG, Wong S-F, Hertz DL. *Journal of Patient Safety*, under review 2020.

# Public Powered Cancer Research

